Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN ES 600 versus PIPRACIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN ES 600 versus PIPRACIL.
AUGMENTIN ES-600 vs PIPRACIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AUGMENTIN ES-600 is a combination of amoxicillin, a beta-lactam antibiotic, and clavulanate, a beta-lactamase inhibitor. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamase enzymes, preventing degradation of amoxicillin.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), interfering with peptidoglycan cross-linking during cell wall assembly.
90 mg/kg/day orally divided every 12 hours (based on amoxicillin component). Maximum 4000 mg amoxicillin/600 mg clavulanate per day.
3.375 g IV every 6 hours (piperacillin 3 g + tazobactam 0.375 g) over 30 minutes; for nosocomial pneumonia: 4.5 g IV every 6 hours over 30 minutes.
None Documented
None Documented
Amoxicillin: ~1.0-1.5 hours in adults with normal renal function; clavulanate: ~1.0-1.2 hours. In renal impairment, half-life prolongs significantly (amoxicillin up to 7-20 hours in ESRD).
0.7-1.2 hours in adults with normal renal function; prolonged to 3-6 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-4 hours.
Amoxicillin: ~50-70% excreted unchanged renally via glomerular filtration and tubular secretion; clavulanate: ~25-40% excreted unchanged renally. Combined: renal excretion accounts for ~60-80% of elimination, with minor biliary/fecal elimination (approx 5-15% for amoxicillin).
Primarily renal (tubular secretion and glomerular filtration) as unchanged drug (50-70%); biliary/fecal excretion is a minor route (approximately 10-20% as unchanged drug and metabolites).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic